semaglutide launch title Today we launch, Obeda®, India's first DCGI-approved generic injection for Type 2 Diabetes. This product reinforces our purpose of good health cant wait, to bring high quality and affordable treatment Business | Danish drugmaker Novo

In a statement published on 11 June 2026, the MHRA said that the drug the first oral glucagon-like peptide-1 (GLP-1) available in the UK can be used in adults with obesity, who have a BMI of 30 or above, or who are overweight with a BMI between 27 and 30 and at least one weight-related comorbidity

Glp1r Tie2/ mice were generated by crossing Glp1r fl/fl mice with Tg (Tek-Cre)1Ywa ( Tie2) Cre mice (Jackson Laboratory, 008863) to target endothelial and immune cells in the Tie2 domain, as previously described (25, 26)

In pivotal trials, weekly semaglutide produced roughly 1415% body-weight reduction at 68 weeks (STEP 1, NEJM 2021), and tirzepatide a dual GIP/GLP-1 co-agonist reached 1822% at one year (SURMOUNT-1, NEJM 2022)

The mice ran longer and faster on treadmill VO 2 max testing

Antidepressant medications, such as selective serotonin reuptake inhibitors (SSRIs) like fluoxetine (Prozac) and sertraline (Zoloft), may be prescribed to manage these symptoms

Retatrutide, the triple-agonist GLP-1/GIP/glucagon receptor peptide, presents unique storage challenges that go beyond what most researchers expect